Krystal Biotech Stock Forecast, Price & News

-1.41 (-2.36 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume75,889 shs
Average Volume118,679 shs
Market Capitalization$1.30 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive KRYS News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

Krystal Biotech logo

About Krystal Biotech

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx for other rare lung disease. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.27 out of 5 stars

Medical Sector

130th out of 842 stocks

Biological Products, Except Diagnostic Industry

22nd out of 103 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions

Is Krystal Biotech a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Krystal Biotech stock.
View analyst ratings for Krystal Biotech
or view top-rated stocks.

What stocks does MarketBeat like better than Krystal Biotech?

Wall Street analysts have given Krystal Biotech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Krystal Biotech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Krystal Biotech's next earnings date?

Krystal Biotech is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Krystal Biotech

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) posted its earnings results on Sunday, May, 9th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by $0.12.
View Krystal Biotech's earnings history

How has Krystal Biotech's stock price been impacted by COVID-19?

Krystal Biotech's stock was trading at $49.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KRYS stock has increased by 17.1% and is now trading at $58.44.
View which stocks have been most impacted by COVID-19

What price target have analysts set for KRYS?

6 brokers have issued twelve-month price targets for Krystal Biotech's shares. Their forecasts range from $90.00 to $115.00. On average, they expect Krystal Biotech's share price to reach $101.00 in the next twelve months. This suggests a possible upside of 72.8% from the stock's current price.
View analysts' price targets for Krystal Biotech
or view top-rated stocks among Wall Street analysts.

Who are Krystal Biotech's key executives?

Krystal Biotech's management team includes the following people:
  • Mr. Krish S. Krishnan, Chairman, Pres & CEO (Age 56, Pay $752.37k)
  • Ms. Suma M. Krishnan, Founder, COO & Director (Age 56, Pay $532.27k)
  • Ms. Kathryn A. Romano, Chief Accounting Officer (Age 40, Pay $200.87k)
  • Ms. Gloria Lin, Accounting Mang.
  • Mr. John Karakkal, VP of North American Sales and Marketing
  • Ms. Katherine Tuminello, HR & Office Mang.
  • Mr. Josh Suskin, Director of HR & Operations
  • Ms. Pooja Agarwal, Sr. VP of Product Devel. (Age 42)
  • Ms. Whitney Glad Ijem, Sr. VP of Strategy & Bus. Devel.
  • Dr. Andreas C. Orth, Chief Commercial Officer

Who are some of Krystal Biotech's key competitors?

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by many different retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (0.09%). Company insiders that own Krystal Biotech stock include Daniel Janney, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends for Krystal Biotech

Which major investors are buying Krystal Biotech stock?

KRYS stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P..
View insider buying and selling activity for Krystal Biotech
or or view top insider-buying stocks.

How do I buy shares of Krystal Biotech?

Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $58.44.

How much money does Krystal Biotech make?

Krystal Biotech has a market capitalization of $1.30 billion. The company earns $-32,170,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

How many employees does Krystal Biotech have?

Krystal Biotech employs 75 workers across the globe.

What is Krystal Biotech's official website?

The official website for Krystal Biotech is

Where are Krystal Biotech's headquarters?

Krystal Biotech is headquartered at 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830 or via email at [email protected]

This page was last updated on 7/31/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.